By 
xStep, the neurotechnology company that made an emotional impression on Shark Tank India earlier this year, has raised fresh funding from Titan Capital, the investment firm run by Snapdeal founders Kunal Bahl and Rohit Bansal. The amount was not disclosed, but the backing is notable partly because Bahl was among the sharks who first invested in xStep on the show. This is a repeat vote of confidence in a company chasing one of the harder problems in medicine.
The idea behind xStep is a compelling one. Many people with neurological conditions such as spinal cord injury, cerebral palsy, stroke, or multiple sclerosis lose movement not because their muscles have failed but because the signals between brain, spinal cord, and muscle are disrupted. xStep delivers gentle electrical stimulation through electrodes placed on the skin over the spinal cord, no surgery involved, to help those circuits communicate again during structured rehabilitation. Its founder, Dr. Parag Gad, spent close to two decades researching exactly this at UCLA, in a lab with a distinguished lineage in spinal stimulation, before returning to India to build the company.
A real mission, and real regulatory footing
The access problem xStep is targeting is real. Advanced neurorehabilitation is scarce and expensive, and largely out of reach for most patients in emerging markets. Making a non-invasive, more affordable option available through clinics, and now through a dedicated rehabilitation centre in Bengaluru that pairs xStep with a robotic gait trainer for children, is a meaningful step. The technology also has genuine regulatory standing: it is approved by India’s drug regulator for clinical and home use and has received the US FDA’s Breakthrough Device designation.
That designation is worth understanding precisely, though, because it is easy to misread. Breakthrough status is a fast-track review pathway for promising devices; it is not the same as full FDA approval, and it is not proof that the therapy works for everyone.
Promise, held honestly
This is where care matters, because the people reading about xStep include families desperate for good news. Non-invasive spinal stimulation is a legitimate and actively researched field, and xStep has produced encouraging results, with some patients showing improvements in movement, sometimes surprisingly quickly. But the company itself is still running more than 25 clinical studies across 20 countries, and a chunk of this new funding is earmarked for generating clinical evidence. That tells you the science is promising and still being proven, not settled. Talk of a “responder rate” is honest in its way: it means some people respond, and some do not.
None of that diminishes what xStep is attempting. A credible scientist building affordable, non-invasive neurorehab from India, for the world, is exactly the kind of hard, patient, deep-tech work that deserves backing, and Titan Capital’s follow-on suggests the commercial plan is holding up alongside the science.
So is xStep a breakthrough for people who have lost movement, or a promising therapy still earning its proof? In truth, it is best understood as the second on its way, perhaps, to becoming the first, if the evidence holds. The mission is worth cheering, the pedigree is real, and the money will help. The most respectful thing to say about a technology like this is also the most accurate: hopeful, advancing, and not yet a finished promise.
Comments